Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
作者:Zenichi Ikeda、Taku Kamei、Yusuke Sasaki、Matthew Reynolds、Nozomu Sakai、Masato Yoshikawa、Michiko Tawada、Nao Morishita、Douglas R. Dougan、Chien-Hung Chen、Irena Levin、Hua Zou、Masako Kuno、Naoto Arimura、Yusuke Kikukawa、Mitsuyo Kondo、Kimio Tohyama、Kenjiro Sato
DOI:10.1021/acs.jmedchem.3c00348
日期:2023.5.11
1-aminophthalazine led to identification of (R)-8 as a potent, selective, orally available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation induced by human serum in a dose-dependent manner in an in vitro assay system, proving that selective C1s inhibition blocked the classical complement pathway effectively. As a result, (R)-8 emerged as a valuable
一系列新型非脒基 C1s 抑制剂已得到探索。从高通量筛选命中3开始,异喹啉被1-氨基酞嗪取代,以增强C1s抑制活性,同时对其他丝氨酸蛋白酶表现出良好的选择性。我们首先公开了 C1s 和小分子抑制剂 ( 4e ) 复合物的晶体结构,该结构指导围绕 S2 和 S3 位点进行基于结构的优化,进一步将 C1s 抑制活性增强 300 倍以上。通过在 1-氨基酞嗪 8 位掺入氟来改善膜通透性,从而将( R )-8鉴定为一种有效的、选择性的、口服的、脑可渗透的 C1s 抑制剂。( R)-8在体外检测系统中以剂量依赖性方式显着抑制人血清诱导的膜攻击复合物形成,证明选择性 C1s 抑制有效阻断经典补体途径。因此,( R )-8成为体外和体内评估的有价值的工具化合物。